深圳市祥根生物

Xianggen Biology is a biotechnology company headquartered in Shenzhen, China, dedicated to the discovery and development of innovative protein degradation therapies. The company leverages its proprietary Proteolysis Targeting Chimera (PROTAC) and molecular glue platforms to target proteins that are traditionally considered "undruggable." Its primary therapeutic focus is oncology, with a pipeline featuring degraders for the androgen receptor and estrogen receptor to treat prostate and breast cancers, respectively. Founded in 2018 by Dr. Xiangyang Ye, a veteran in medicinal chemistry with experience at GSK and Novartis, the firm aims to address unmet medical needs and overcome drug resistance in cancer treatment. Xianggen Biology has successfully secured multiple rounds of venture capital funding from prominent investors like Lapam Capital and Shenzhen Capital Group to advance its early-stage programs. The company's research efforts are centered on creating highly selective and potent small molecules that utilize the ubiquitin-proteasome system for targeted protein degradation.